Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 8, 2011, Pages 867-878

  Claudel, Thierry ^a   Zollner, Gernot ^a   Wagner, Martin ^a   Trauner, Michael ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bile acid transport; Bile acids; Cholestasis; FXR; Gallstone; Nuclear receptors

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450 2B; CYTOCHROME P450 3A11; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4;

BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE SECRETION; CELL TRANSPORT; CHOLELITHIASIS; CHOLESTASIS; HEPATITIS; HEREDITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; BILE; BILE ACIDS AND SALTS; CHOLESTASIS; GALLSTONES; HEPATOCYTES; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79958263832     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.12.021     Document Type: Review

References (278)

1. Hofmann A.F. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 1999, 14:24-29.
2. Claudel T., Staels B., Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2020-2030.
3. Fiorucci S., Rizzo G., Donini A., Distrutti E., Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 2007, 13:298-309.
4. Lo Sasso G., Petruzzelli M., Moschetta A. A translational view on the biliary lipid secretory network. Biochim. Biophys. Acta 2008, 1781:79-96.
5. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
6. Seol W., Choi H.S., Moore D.D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 1995, 9:72-85.
7. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
8. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., Lehmann J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
9. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3:543-553.
10. Otte K., Kranz H., Kober I., Thompson P., Hoefer M., Haubold B., Remmel B., Voss H., Kaiser C., Albers M., Cheruvallath Z., Jackson D., Casari G., Koegl M., Paabo S., Mous J., Kremoser C., Deuschle U. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell. Biol. 2003, 23:864-872.
11. Laffitte B.A., Kast H.R., Nguyen C.M., Zavacki A.M., Moore D.D., Edwards P.A. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J. Biol. Chem. 2000, 275:10638-10647.
12. Claudel T., Sturm E., Duez H., Torra I.P., Sirvent A., Kosykh V., Fruchart J.C., Dallongeville J., Hum D.W., Kuipers F., Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 2002, 109:961-971.
13. Barbier O., Torra I.P., Sirvent A., Claudel T., Blanquart C., Duran-Sandoval D., Kuipers F., Kosykh V., Fruchart J.C., Staels B. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003, 124:1926-1940.
14. Lu Y., Heydel J.M., Li X., Bratton S., Lindblom T., Radominska-Pandya A. Lithocholic acid decreases expression of ugt2b7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element. Drug Metab. Dispos. 2005, 33:937-946.
15. Chong H.K., Infante A.M., Seo Y.K., Jeon T.I., Zhang Y., Edwards P.A., Xie X., Osborne T.F. Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. Nucleic Acids Res. 2010, 38:6007-6017.
16. Thomas A.M., Hart S.N., Kong B., Fang J., Zhong X.B., Guo G.L. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 2010, 51:1410-1419.
17. Huber R.M., Murphy K., Miao B., Link J.R., Cunningham M.R., Rupar M.J., Gunyuzlu P.L., Haws T.F., Kassam A., Powell F., Hollis G.F., Young P.R., Mukherjee R., Burn T.C. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002, 290:35-43.
18. Zhang Y., Kast-Woelbern H.R., Edwards P.A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 2003, 278:104-110.
19. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
20. Kim I., Ahn S.H., Inagaki T., Choi M., Ito S., Guo G.L., Kliewer S.A., Gonzalez F.J. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 2007, 48:2664-2672.
21. Kok T., Hulzebos C.V., Wolters H., Havinga R., Agellon L.B., Stellaard F., Shan B., Schwarz M., Kuipers F. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J. Biol. Chem. 2003, 278:41930-41937.
22. Zollner G., Fickert P., Fuchsbichler A., Silbert D., Wagner M., Arbeiter S., Gonzalez F.J., Marschall H.U., Zatloukal K., Denk H., Trauner M. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J. Hepatol. 2003, 39:480-488.
23. Schuetz E.G., Strom S., Yasuda K., Lecureur V., Assem M., Brimer C., Lamba J., Kim R.B., Ramachandran V., Komoroski B.J., Venkataramanan R., Cai H., Sinal C.J., Gonzalez F.J., Schuetz J.D. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 2001, 276:39411-39418.
24. Marschall H.U., Wagner M., Bodin K., Zollner G., Fickert P., Gumhold J., Silbert D., Fuchsbichler A., Sjovall J., Trauner M. Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J. Lipid Res. 2006, 47:582-592.
25. Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., LaTour A., Liu Y., Klaassen C.D., Brown K.K., Reinhard J., Willson T.M., Koller B.H., Kliewer S.A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 2001, 98:3369-3374.
26. Xie W., Radominska-Pandya A., Shi Y., Simon C.M., Nelson M.C., Ong E.S., Waxman D.J., Evans R.M. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl Acad. Sci. USA 2001, 98:3375-3380.
27. Stedman C.A., Liddle C., Coulter S.A., Sonoda J., Alvarez J.G., Moore D.D., Evans R.M., Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl Acad. Sci. USA 2005, 102:2063-2068.
28. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., Haussler M.R., Mangelsdorf D.J. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
29. Nishida S., Ozeki J., Makishima M. Modulation of bile acid metabolism by 1{alpha}-hydroxyvitamin D3 administration in mice. Drug Metab. Dispos. 2009.
30. Ishizawa M., Matsunawa M., Adachi R., Uno S., Ikeda K., Masuno H., Shimizu M., Iwasaki K., Yamada S., Makishima M. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J. Lipid Res. 2008, 49:763-772.
31. Guo G.L., Lambert G., Negishi M., Ward J.M., Brewer H.B., Kliewer S.A., Gonzalez F.J., Sinal C.J. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 2003, 278:45062-45071.
32. Zhang J., Huang W., Qatanani M., Evans R.M., Moore D.D. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 2004, 279:49517-49522.
33. Wagner M., Halilbasic E., Marschall H.U., Zollner G., Fickert P., Langner C., Zatloukal K., Denk H., Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005, 42:420-430.
34. Uppal H., Toma D., Saini S.P., Ren S., Jones T.J., Xie W. Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 2005, 41:168-176.
35. Song C., Liao S. Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 2000, 141:4180-4184.
36. Song C., Hiipakka R.A., Liao S. Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 2000, 65:423-427.
37. Esteller A. Physiology of bile secretion. World J. Gastroenterol. 2008, 14:5641-5649.
38. Hofmann A.F. Biliary secretion and excretion in health and disease: current concepts. Ann. Hepatol. 2007, 6:15-27.
39. Trauner M., Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 2003, 83:633-671.
40. Hofmann A.F. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 1999, 159:2647-2658.
41. Nathanson M.H., Boyer J.L. Mechanisms and regulation of bile secretion. Hepatology 1991, 14:551-566.
42. Baiocchi L., LeSage G., Glaser S., Alpini G. Regulation of cholangiocyte bile secretion. J. Hepatol. 1999, 31:179-191.
43. Marzioni M., Glaser S.S., Francis H., Phinizy J.L., LeSage G., Alpini G. Functional heterogeneity of cholangiocytes. Semin. Liver Dis. 2002, 22:227-240.
44. Lazaridis K.N., Strazzabosco M., Larusso N.F. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004, 127:1565-1577.
45. Kullak-Ublick G.A., Stieger B., Meier P.J. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004, 126:322-342.
46. Trauner M., Wagner M., Fickert P., Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 2005, 39:S111-S124.
47. Yoon Y.B., Hagey L.R., Hofmann A.F., Gurantz D., Michelotti E.L., Steinbach J.H. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986, 90:837-852.
48. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 2003, 72:137-174.
49. Ramirez M.I., Karaoglu D., Haro D., Barillas C., Bashirzadeh R., Gil G. Cholesterol and bile acids regulate cholesterol 7 alpha-hydroxylase expression at the transcriptional level in culture and in transgenic mice. Mol. Cell. Biol. 1994, 14:2809-2821.
50. Chiang J.Y. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 2004, 40:539-551.
51. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272:3137-3140.
52. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
53. Le Martelot G., Claudel T., Gatfield D., Schaad O., Kornmann B., Sasso G.L., Moschetta A., Schibler U. REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol. 2009, 7:e1000181.
54. Mitropoulos K.A., Balasubramaniam S., Gibbons G.F., Reeves B.E. Diurnal variation in the activity of cholesterol 7 -hydroxylase in the livers of fed and fasted rats. FEBS Lett. 1972, 27:203-206.
55. Chiang J.Y., Miller W.F., Lin G.M. Regulation of cholesterol 7 alpha-hydroxylase in the liver. Purification of cholesterol 7 alpha-hydroxylase and the immunochemical evidence for the induction of cholesterol 7 alpha-hydroxylase by cholestyramine and circadian rhythm. J. Biol. Chem. 1990, 265:3889-3897.
56. Noshiro M., Nishimoto M., Okuda K. Rat liver cholesterol 7 alpha-hydroxylase. Pretranslational regulation for circadian rhythm. J. Biol. Chem. 1990, 265:10036-10041.
57. Russell D.W. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 2009, 50(Suppl):S120-S125.
58. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89:147-191.
59. Park Y.J., Qatanani M., Chua S.S., LaRey J.L., Johnson S.A., Watanabe M., Moore D.D., Lee Y.K. Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis. Hepatology 2008, 47:1578-1586.
60. Chiang J.Y., Kimmel R., Weinberger C., Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 2000, 275:10918-10924.
61. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., Galardi C., Wilson J.G., Lewis M.C., Roth M.E., Maloney P.R., Willson T.M., Kliewer S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6:517-526.
62. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., Mangelsdorf D.J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 2000, 6:507-515.
63. del Castillo-Olivares A., Gil G. Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydroxylase transcription. Nucleic Acids Res. 2000, 28:3587-3593.
64. Zhang M., Chiang J.Y. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1). Roles of hepatocyte nuclear receptor 4alpha in mediating bile acid repression. J. Biol. Chem. 2001, 276:41690-41699.
65. Mataki C., Magnier B.C., Houten S.M., Annicotte J.S., Argmann C., Thomas C., Overmars H., Kulik W., Metzger D., Auwerx J., Schoonjans K. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol. Cell. Biol. 2007, 27:8330-8339.
66. Lee Y.K., Schmidt D.R., Cummins C.L., Choi M., Peng L., Zhang Y., Goodwin B., Hammer R.E., Mangelsdorf D.J., Kliewer S.A. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol. Endocrinol. 2008, 22:1345-1356.
67. Jung D., Kullak-Ublick G.A. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 2003, 37:622-631.
68. De Fabiani E., Mitro N., Gilardi F., Caruso D., Galli G., Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 2003, 278:39124-39132.
69. Kesaniemi Y.A., Grundy S.M. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984, 251:2241-2246.
70. Marrapodi M., Chiang J.Y. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 2000, 41:514-520.
71. Post S.M., Duez H., Gervois P.P., Staels B., Kuipers F., Princen H.M. Fibrates suppress bile acid synthesis via peroxisome proliferator- activated receptor-alpha-mediated downregulation of cholesterol 7alpha- hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1840-1845.
72. Patel D.D., Knight B.L., Soutar A.K., Gibbons G.F., Wade D.P. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. Biochem. J. 2000, 351(Pt 3):747-753.
73. Cheema S.K., Agellon L.B. The murine and human cholesterol 7alpha-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 2000, 275:12530-12536.
74. Hunt M.C., Yang Y.Z., Eggertsen G., Carneheim C.M., Gafvels M., Einarsson C., Alexson S.E. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J. Biol. Chem. 2000, 275:28947-28953.
75. Roglans N., Vazquez-Carrera M., Alegret M., Novell F., Zambon D., Ros E., Laguna J.C., Sanchez R.M. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 2004, 59:855-861.
76. Gupta S., Stravitz R.T., Dent P., Hylemon P.B. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J. Biol. Chem. 2001, 276:15816-15822.
77. De Fabiani E., Mitro N., Anzulovich A.C., Pinelli A., Galli G., Crestani M. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J. Biol. Chem. 2001, 276:30708-30716.
78. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., Gerard R.D., Repa J.J., Mangelsdorf D.J., Kliewer S.A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-225.
79. Yu C., Wang F., Kan M., Jin C., Jones R.B., Weinstein M., Deng C.X., McKeehan W.L. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 2000, 275:15482-15489.
80. Holt J.A., Luo G., Billin A.N., Bisi J., McNeill Y.Y., Kozarsky K.F., Donahee M., Wang da Y., Mansfield T.A., Kliewer S.A., Goodwin B., Jones S.A. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-1591.
81. Schaap F.G., van der Gaag N.A., Gouma D.J., Jansen P.L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009, 49:1228-1235.
82. Ito S., Fujimori T., Furuya A., Satoh J., Nabeshima Y., Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 2005, 115:2202-2208.
83. Lin B.C., Wang M., Blackmore C., Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 2007, 282:27277-27284.
84. Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 2007, 282:26687-26695.
85. Wu X., Ge H., Gupte J., Weiszmann J., Shimamoto G., Stevens J., Hawkins N., Lemon B., Shen W., Xu J., Veniant M.M., Li Y.S., Lindberg R., Chen J.L., Tian H., Li Y. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 2007, 282:29069-29072.
86. Walters J.R., Tasleem A.M., Omer O.S., Brydon W.G., Dew T., le Roux C.W. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol. 2009, 7:1189-1194.
87. Jung D., Inagaki T., Dawson P.A., Kliewer S.A., Mangelsdorf D.J., Moschetta A. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 2007, 48:2693-2700.
88. Shoda J., Kano M., Oda K., Kamiya J., Nimura Y., Suzuki H., Sugiyama Y., Miyazaki H., Todoroki T., Stengelin S., Kramer W., Matsuzaki Y., Tanaka N. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am. J. Gastroenterol. 2001, 96:3368-3378.
89. Bremmelgaard A., Sjovall J. Bile acid profiles in urine of patients with liver diseases. Eur. J. Clin. Invest. 1979, 9:341-348.
90. Bodin K., Lindbom U., Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim. Biophys. Acta 2005, 1687:84-93.
91. Handschin C., Meyer U.A. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 2003, 55:649-673.
92. Drocourt L., Ourlin J.C., Pascussi J.M., Maurel P., Vilarem M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 2002, 277:25125-25132.
93. Goodwin B., Hodgson E., D'Costa D.J., Robertson G.R., Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 2002, 62:359-365.
94. Gnerre C., Blattler S., Kaufmann M.R., Looser R., Meyer U.A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004, 14:635-645.
95. Weinshilboum R.M., Otterness D.M., Aksoy I.A., Wood T.C., Her C., Raftogianis R.B. Sulfation and sulfotransferases 1: sulfotransferase molecular biology: cDNAs and genes. FASEB J. 1997, 11:3-14.
96. Falany C.N. Enzymology of human cytosolic sulfotransferases. FASEB J. 1997, 11:206-216.
97. Thomassen P.A. Urinary bile acids in late pregnancy and in recurrent cholestasis of pregnancy. Eur. J. Clin. Invest. 1979, 9:425-432.
98. Makino I., Hashimoto H., Shinozaki K., Yoshino K., Nakagawa S. Sulfated and nonsulfated bile acids in urine, serum, and bile of patients with hepatobiliary diseases. Gastroenterology 1975, 68:545-553.
99. van Berge Henegouwen G.P., Brandt K.H., Eyssen H., Parmentier G. Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis. Gut 1976, 17:861-869.
100. Song C.S., Echchgadda I., Baek B.S., Ahn S.C., Oh T., Roy A.K., Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 2001, 276:42549-42556.
101. Sonoda J., Xie W., Rosenfeld J.M., Barwick J.L., Guzelian P.S., Evans R.M. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor. Proc. Natl Acad. Sci. USA 2002, 99:13801-13806.
102. Echchgadda I., Song C.S., Roy A.K., Chatterjee B. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 2004, 65:720-729.
103. Assem M., Schuetz E.G., Leggas M., Sun D., Yasuda K., Reid G., Zelcer N., Adachi M., Strom S., Evans R.M., Moore D.D., Borst P., Schuetz J.D. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 2004, 279:22250-22257.
104. Saini S.P., Sonoda J., Xu L., Toma D., Uppal H., Mu Y., Ren S., Moore D.D., Evans R.M., Xie W. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 2004, 65:292-300.
105. Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. Pharmacol. Sci. 2005, 97:177-183.
106. Fang H.L., Strom S.C., Cai H., Falany C.N., Kocarek T.A., Runge-Morris M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 2005, 67:1257-1267.
107. Takikawa H., Beppu T., Seyama Y. Urinary concentrations of bile acid glucuronides and sulfates in hepatobiliary diseases. Gastroenterol. Jpn 1984, 19:104-109.
108. Frohling W., Stiehl A. Bile salt glucuronides: identification and quantitative analysis in the urine of patients with cholestasis. Eur. J. Clin. Invest. 1976, 6:67-74.
109. Barbier O., Duran-Sandoval D., Pineda-Torra I., Kosykh V., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 2003, 278:32852-32860.
110. Trottier J., Verreault M., Grepper S., Monte D., Belanger J., Kaeding J., Caron P., Inaba T.T., Barbier O. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 2006, 44:1158-1170.
111. Marschall H.U., Matern H., Egestad B., Matern S., Sjovall S. 6 alpha-glucuronidation of hyodeoxycholic acid by human liver, kidney and small bowel microsomes. Biochim. Biophys. Acta 1987, 921:392-397.
112. Marschall H.U., Matern H., Wietholtz H., Egestad B., Matern S., Sjovall J. Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans. J. Clin. Invest. 1992, 89:1981-1987.
113. Wietholtz H., Marschall H.U., Sjovall J., Matern S. Stimulation of bile acid 6 alpha-hydroxylation by rifampin. J. Hepatol. 1996, 24:713-718.
114. Jung D., Hagenbuch B., Fried M., Meier P.J., Kullak-Ublick G.A. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:G752-G761.
115. Ganguly T.C., O'Brien M.L., Karpen S.J., Hyde J.F., Suchy F.J., Vore M. Regulation of the rat liver sodium-dependent bile acid cotransporter gene by prolactin. Mediation of transcriptional activation by Stat5. J. Clin. Invest. 1997, 99:2906-2914.
116. Zollner G., Fickert P., Silbert D., Fuchsbichler A., Stumptner C., Zatloukal K., Denk H., Trauner M. Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G184-G191.
117. Geier A., Zollner G., Dietrich C.G., Wagner M., Fickert P., Denk H., van Rooijen N., Matern S., Gartung C., Trauner M. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. Hepatology 2005, 41:470-477.
118. Denson L.A., Sturm E., Echevarria W., Zimmerman T.L., Makishima M., Mangelsdorf D.J., Karpen S.J. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001, 121:140-147.
119. Lee Y.K., Dell H., Dowhan D.H., Hadzopoulou-Cladaras M., Moore D.D. The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression. Mol. Cell. Biol. 2000, 20:187-195.
120. Wang L., Lee Y.K., Bundman D., Han Y., Thevananther S., Kim C.S., Chua S.S., Wei P., Heyman R.A., Karin M., Moore D.D. Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell 2002, 2:721-731.
121. Li D., Zimmerman T.L., Thevananther S., Lee H.Y., Kurie J.M., Karpen S.J. Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent. J. Biol. Chem. 2002, 277:31416-31422.
122. Eloranta J.J., Jung D., Kullak-Ublick G.A. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol. Endocrinol. 2006, 20:65-79.
123. Shneider B.L., Fox V.L., Schwarz K.B., Watson C.L., Ananthanarayanan M., Thevananther S., Christie D.M., Hardikar W., Setchell K.D., Mieli-Vergani G., Suchy F.J., Mowat A.P. Hepatic basolateral sodium-dependent-bile acid transporter expression in two unusual cases of hypercholanemia and in extrahepatic biliary atresia. Hepatology 1997, 25:1176-1183.
124. Zollner G., Fickert P., Zenz R., Fuchsbichler A., Stumptner C., Kenner L., Ferenci P., Stauber R.E., Krejs G.J., Denk H., Zatloukal K., Trauner M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001, 33:633-646.
125. Zollner G., Fickert P., Silbert D., Fuchsbichler A., Marschall H.U., Zatloukal K., Denk H., Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 2003, 38:717-727.
126. Zollner G., Marschall H.U., Wagner M., Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 2006, 3:231-251.
127. Jung D., Podvinec M., Meyer U.A., Mangelsdorf D.J., Fried M., Meier P.J., Kullak-Ublick G.A. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 2002, 122:1954-1966.
128. Kullak-Ublick G.A., Stieger B., Hagenbuch B., Meier P.J. Hepatic transport of bile salts. Semin. Liver Dis. 2000, 20:273-292.
129. Meier P.J., Stieger B. Bile salt transporters. Annu. Rev. Physiol. 2002, 64:635-661.
130. Keppler D., Konig J. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 2000, 20:265-272.
131. Cui Y., Konig J., Buchholz J.K., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 1999, 55:929-937.
132. Dubuisson C., Cresteil D., Desrochers M., Decimo D., Hadchouel M., Jacquemin E. Ontogenic expression of the Na(+)-independent organic anion transporting polypeptide (oatp) in rat liver and kidney. J. Hepatol. 1996, 25:932-940.
133. Elferink R.P., Ottenhoff R., van Marle J., Frijters C.M., Smith A.J., Groen A.K. Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. J. Clin. Invest. 1998, 102:1749-1757.
134. Riordan J.R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985, 316:817-819.
135. Ueda K., Cornwell M.M., Gottesman M.M., Pastan I., Roninson I.B., Ling V., Riordan J.R. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun. 1986, 141:956-962.
136. Ruetz S., Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994, 77:1071-1081.
137. Van der Bliek A.M., Baas F., Ten Houte de Lange T., Kooiman P.M., Van der Vel de-Koerts T., Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J. 1987, 6:3325-3331.
138. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., Kwiterovich P., Shan B., Barnes R., Hobbs H.H. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
139. Lee M.H., Lu K., Hazard S., Yu H., Shulenin S., Hidaka H., Kojima H., Allikmets R., Sakuma N., Pegoraro R., Srivastava A.K., Salen G., Dean M., Patel S.B. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet. 2001, 27:79-83.
140. Yu L., Li-Hawkins J., Hammer R.E., Berge K.E., Horton J.D., Cohen J.C., Hobbs H.H. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 2002, 110:671-680.
141. Bull L.N., van Eijk M.J., Pawlikowska L., DeYoung J.A., Juijn J.A., Liao M., Klomp L.W., Lomri N., Berger R., Scharschmidt B.F., Knisely A.S., Houwen R.H., Freimer N.B. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 1998, 18:219-224.
142. Pawlikowska L., Groen A., Eppens E.F., Kunne C., Ottenhoff R., Looije N., Knisely A.S., Killeen N.P., Bull L.N., Elferink R.P., Freimer N.B. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum. Mol. Genet. 2004, 13:881-892.
143. Demuth D.R., Showe L.C., Ballantine M., Palumbo A., Fraser P.J., Cioe L., Rovera G., Curtis P.J. Cloning and structural characterization of a human non-erythroid band 3-like protein. EMBO J. 1986, 5:1205-1214.
144. Palumbo A.P., Isobe M., Huebner K., Shane S., Rovera G., Demuth D., Curtis P.J., Ballantine M., Croce C.M., Showe L.C. Chromosomal localization of a human band 3-like gene to region 7q35-7q36. Am. J. Hum. Genet. 1986, 39:307-316.
145. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Weiglein A.H., Lammert F., Marschall H.U., Tsybrovskyy O., Zatloukal K., Denk H., Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123:1238-1251.
146. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J., Suchy F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 2001, 276:28857-28865.
147. Gerloff T., Stieger B., Hagenbuch B., Madon J., Landmann L., Roth J., Hofmann A.F., Meier P.J. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 1998, 273:10046-10050.
148. Plass J.R., Mol O., Heegsma J., Geuken M., Faber K.N., Jansen P.L., Muller M. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 2002, 35:589-596.
149. Wagner M., Fickert P., Zollner G., Fuchsbichler A., Silbert D., Tsybrovskyy O., Zatloukal K., Guo G.L., Schuetz J.D., Gonzalez F.J., Marschall H.U., Denk H., Trauner M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003, 125:825-838.
150. Honjo Y., Sasaki S., Kobayashi Y., Misawa H., Nakamura H. 1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J. Endocrinol. 2006, 188:635-643.
151. Gascon-Barre M., Demers C., Mirshahi A., Neron S., Zalzal S., Nanci A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003, 37:1034-1042.
152. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., Kliewer S., Willson T.M., Edwards P.A. Regulation of multidrug resistance-associated protein 2 (MRP2; ABCC2) by the nuclear receptors PXR, FXR, and CAR. J. Biol. Chem. 2001, 12:12.
153. Denson L.A., Auld K.L., Schiek D.S., McClure M.H., Mangelsdorf D.J., Karpen S.J. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J. Biol. Chem. 2000, 275:8835-8843.
154. Huang L., Zhao A., Lew J.L., Zhang T., Hrywna Y., Thompson J.R., Pedro Nd N., Royo I., Blevins R.A., Pelaez F., Wright S.D., Cui J. Farnesoid X-receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 2003, 278:51085-51090.
155. Kok T., Bloks V.W., Wolters H., Havinga R., Jansen P.L., Staels B., Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 2003, 369:539-547.
156. Trauner M., Fickert P., Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin. Liver Dis. 2007, 27:77-98.
157. Sturm E., Wagner M., Trauner M. Nuclear receptor ligands in therapy of cholestatic liver disease. Front. Biosci. 2009, 14:4299-4325.
158. Wagner M., Zollner G., Trauner M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 2009, 51:565-580.
159. Ballatori N., Christian W.V., Lee J.Y., Dawson P.A., Soroka C.J., Boyer J.L., Madejczyk M.S., Li N. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005, 42:1270-1279.
160. Mennone A., Soroka C.J., Cai S.Y., Harry K., Adachi M., Hagey L., Schuetz J.D., Boyer J.L. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006, 43:1013-1021.
161. Zelcer N., van de Wetering K., de Waart R., Scheffer G.L., Marschall H.U., Wielinga P.R., Kuil A., Kunne C., Smith A., van der Valk M., Wijnholds J., Elferink R.O., Borst P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 2006, 44:768-775.
162. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., MacKenzie K.I., Mansfield T.A., Kliewer S.A., Goodwin B., Jones S.A. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 2003, 112:1678-1687.
163. Teng S., Jekerle V., Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 2003, 31:1296-1299.
164. McCarthy T.C., Li X., Sinal C.J. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J. Biol. Chem. 2005, 280:23232-23242.
165. Cherrington N.J., Hartley D.P., Li N., Johnson D.R., Klaassen C.D. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J. Pharmacol. Exp. Ther. 2002, 300:97-104.
166. Maher J.M., Cheng X., Slitt A.L., Dieter M.Z., Klaassen C.D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 2005, 33:956-962.
167. Boyer J.L., Trauner M., Mennone A., Soroka C.J., Cai S.Y., Moustafa T., Zollner G., Lee J.Y., Ballatori N. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G1124-G1130.
168. Lee H., Zhang Y., Lee F.Y., Nelson S.F., Gonzalez F.J., Edwards P.A. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J. Lipid Res. 2006, 47:201-214.
169. Landrier J.F., Eloranta J.J., Vavricka S.R., Kullak-Ublick G.A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G476-G485.
170. Alpini G., Lenzi R., Sarkozi L., Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J. Clin. Invest. 1988, 81:569-578.
171. Alpini G., Lenzi R., Zhai W.R., Slott P.A., Liu M.H., Sarkozi L., Tavoloni N. Bile secretory function of intrahepatic biliary epithelium in the rat. Am. J. Physiol. 1989, 257:G124-G133.
172. Banales J.M., Prieto J., Medina J.F. Cholangiocyte anion exchange and biliary bicarbonate excretion. World J. Gastroenterol. 2006, 12:3496-3511.
173. Strazzabosco M., Fabris L., Spirli C. Pathophysiology of cholangiopathies. J. Clin. Gastroenterol. 2005, 39:S90-S102.
174. LeSage G., Glaser S., Alpini G. Regulation of cholangiocyte proliferation. Liver 2001, 21:73-80.
175. Alpini G., Glaser S.S., Rodgers R., Phinizy J.L., Robertson W.E., Lasater J., Caligiuri A., Tretjak Z., LeSage G.D. Functional expression of the apical Na+-dependent bile acid transporter in large but not small rat cholangiocytes. Gastroenterology 1997, 113:1734-1740.
176. Lazaridis K.N., Pham L., Tietz P., Marinelli R.A., deGroen P.C., Levine S., Dawson P.A., LaRusso N.F. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J. Clin. Invest. 1997, 100:2714-2721.
177. Soroka C.J., Lee J.M., Azzaroli F., Boyer J.L. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001, 33:783-791.
178. Kool M., van der Linden M., de Haas M., Scheffer G.L., de Vree J.M., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Elferink R.P., Baas F., Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl Acad. Sci. USA 1999, 96:6914-6919.
179. Chignard N., Mergey M., Barbu V., Finzi L., Tiret E., Paul A., Housset C. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology 2005, 42:549-557.
180. van Erpecum K.J., Wang D.Q., Moschetta A., Ferri D., Svelto M., Portincasa P., Hendrickx J.J., Schipper M., Calamita G. Gallbladder histopathology during murine gallstone formation: relation to motility and concentrating function. J. Lipid Res. 2006, 47:32-41.
181. Arrese M., Trauner M., Sacchiero R.J., Crossman M.W., Shneider B.L. Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology 1998, 28:1081-1087.
182. Maeda T., Miyata M., Yotsumoto T., Kobayashi D., Nozawa T., Toyama K., Gonzalez F.J., Yamazoe Y., Tamai I. Regulation of drug transporters by the farnesoid X receptor in mice. Mol. Pharm. 2004, 1:281-289.
183. Stravitz R.T., Sanyal A.J., Pandak W.M., Vlahcevic Z.R., Beets J.W., Dawson P.A. Induction of sodium-dependent bile acid transporter messenger RNA, protein, and activity in rat ileum by cholic acid. Gastroenterology 1997, 113:1599-1608.
184. Chen F., Ma L., Dawson P.A., Sinal C.J., Sehayek E., Gonzalez F.J., Breslow J., Ananthanarayanan M., Shneider B.L. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 2003, 278:19909-19916.
185. Neimark E., Chen F., Li X., Shneider B.L. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 2004, 40:149-156.
186. Jung D., Fantin A.C., Scheurer U., Fried M., Kullak-Ublick G.A. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 2004, 53:78-84.
187. Jung D., Fried M., Kullak-Ublick G.A. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 2002, 277:30559-30566.
188. Tavoloni N. Biliary excretion of inorganic electrolytes: its role in hepatic bile formation. Can. J. Physiol. Pharmacol. 1985, 63:1245-1251.
189. Tavoloni N. Role of ductular bile water reabsorption in canine bile secretion. J. Lab. Clin. Med. 1985, 106:154-161.
190. Arenas F., Hervias I., Uriz M., Joplin R., Prieto J., Medina J.F. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J. Clin. Invest. 2008, 118:695-709.
191. Trauner M., Meier P.J., Boyer J.L. Molecular pathogenesis of cholestasis. N. Engl. J. Med. 1998, 339:1217-1227.
192. Arrese M., Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 2003, 9:558-564.
193. Trauner M., Meier P.J., Boyer J.L. Molecular regulation of hepatocellular transport systems in cholestasis. J. Hepatol. 1999, 31:165-178.
194. Kullak-Ublick G.A., Meier P.J. Mechanisms of cholestasis. Clin. Liver Dis. 2000, 4:357-385.
195. Kosters A., Karpen S.J. The role of inflammation in cholestasis: clinical and basic aspects. Semin. Liver Dis. 2010, 30:186-194.
196. Lee J., Boyer J.L. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin. Liver Dis. 2000, 20:373-384.
197. Wagner M., Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann. Hepatol. 2005, 4:77-99.
198. Geier A., Wagner M., Dietrich C.G., Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 2007, 1773:283-308.
199. Geenes V., Williamson C. Intrahepatic cholestasis of pregnancy. World J. Gastroenterol. 2009, 15:2049-2066.
200. Van Mil S.W., Milona A., Dixon P.H., Mullenbach R., Geenes V.L., Chambers J., Shevchuk V., Moore G.E., Lammert F., Glantz A.G., Mattsson L.A., Whittaker J., Parker M.G., White R., Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007, 133:507-516.
201. Marzolini C., Tirona R.G., Gervasini G., Poonkuzhali B., Assem M., Lee W., Leake B.F., Schuetz J.D., Schuetz E.G., Kim R.B. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 2007, 21:1769-1780.
202. Zimmer V., Mullenbach R., Simon E., Bartz C., Matern S., Lammert F. Combined functional variants of hepatobiliary transporters and FXR aggravate intrahepatic cholestasis of pregnancy. Liver Int. 2009, 29:1286-1288.
203. Heikkinen J. Serum bile acids in the early diagnosis of intrahepatic cholestasis of pregnancy. Obstet. Gynecol. 1983, 61:581-587.
204. Bacq Y., Myara A., Brechot M.C., Hamon C., Studer E., Trivin F., Metman E.H. Serum conjugated bile acid profile during intrahepatic cholestasis of pregnancy. J. Hepatol. 1995, 22:66-70.
205. Brites D., Rodrigues C.M., van-Zeller H., Brito A., Silva R. Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in a high incidence area: Portugal. Eur. J. Obstet. Gynecol. Reprod. Biol. 1998, 80:31-38.
206. Kovacs P., Kress R., Rocha J., Kurtz U., Miquel J.F., Nervi F., Mendez-Sanchez N., Uribe M., Bock H.H., Schirin-Sokhan R., Stumvoll M., Mossner J., Lammert F., Wittenburg H. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J. Hepatol. 2007.
207. Alvarez L., Jara P., Sanchez-Sabate E., Hierro L., Larrauri J., Diaz M.C., Camarena C., De la Vega A., Frauca E., Lopez-Collazo E., Lapunzina P. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 2004, 13:2451-2460.
208. Chen F., Ananthanarayanan M., Emre S., Neimark E., Bull L.N., Knisely A.S., Strautnieks S.S., Thompson R.J., Magid M.S., Gordon R., Balasubramanian N., Suchy F.J., Shneider B.L. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004, 126:756-764.
209. Martinez-Fernandez P., Hierro L., Jara P., Alvarez L. Knockdown of ATP8B1 expression leads to specific down-regulation of the bile acid sensor FXR in HepG2 cells. Effect of the FXR agonist GW4064. Am. J. Physiol. Gastrointest. Liver Physiol. 2009.
210. Frankenberg T., Miloh T., Chen F.Y., Ananthanarayanan M., Sun A.Q., Balasubramaniyan N., Arias I., Setchell K.D., Suchy F.J., Shneider B.L. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 2008, 48:1896-1905.
211. Demeilliers C., Jacquemin E., Barbu V., Mergey M., Paye F., Fouassier L., Chignard N., Housset C., Lomri N.E. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. Hepatology 2006, 43:1125-1134.
212. Cai S.Y., Gautam S., Nguyen T., Soroka C.J., Rahner C., Boyer J.L. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 2008.
213. Karlsen T.H., Lie B.A., Frey Froslie K., Thorsby E., Broome U., Schrumpf E., Boberg K.M. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 2006, 131:781-787.
214. Zollner G., Wagner M., Fickert P., Silbert D., Gumhold J., Zatloukal K., Denk H., Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 2007, 27:920-929.
215. Wagner M., Zollner G., Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis. 2010, 30:160-177.
216. Zollner G., Wagner M., Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol. Ther. 2010, 126:228-243.
217. Trauner M., Fickert P., Baghdasaryan A., Claudel T., Halilbasic E., Moustafa T., Wagner M., Zollner G. New insights into autoimmune cholangitis through animal models. Dig. Dis. 2010, 28:99-104.
218. Hruz P., Zimmermann C., Gutmann H., Degen L., Beuers U., Terracciano L., Drewe J., Beglinger C. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 2006, 55:395-402.
219. Slitt A.L., Allen K., Morrone J., Aleksunes L.M., Chen C., Maher J.M., Manautou J.E., Cherrington N.J., Klaassen C.D. Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim. Biophys. Acta 2007, 1768:637-647.
220. Lee J., Azzaroli F., Wang L., Soroka C.J., Gigliozzi A., Setchell K.D., Kramer W., Boyer J.L. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 2001, 121:1473-1484.
221. Paumgartner G., Pusl T. Medical treatment of cholestatic liver disease. Clin. Liver Dis. 2008, 12:53-80.
222. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders". J. Hepatol. 2001, 35:134-146.
223. Beuers U., Kullak-Ublick G.A., Pusl T., Rauws E.R., Rust C. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?. Clin. Rev. Allergy Immunol. 2009, 36:52-61.
224. Amaral J.D., Viana R.J., Ramalho R.M., Steer C.J., Rodrigues C.M. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J. Lipid Res. 2009, 50:1721-1734.
225. Tanaka H., Makino Y., Miura T., Hirano F., Okamoto K., Komura K., Sato Y., Makino I. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J. Immunol. 1996, 156:1601-1608.
226. Mason A., Luketic V., Lindor K., Hirschfield G., Gordon S., Mayo M., Kowdley K., Parés A., Trauner M., Castelloe E., Sciacca C., Jones T.B., Böhm O., Shapiro D. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of int-747 to ursodeoxycholic acid http://www.kenes.com/easl2010/orals/105.htm.
227. Kremer A.E., Martens J.J., Kulik W., Rueff F., Kuiper E.M., van Buuren H.R., van Erpecum K.J., Kondrackiene J., Prieto J., Rust C., Geenes V.L., Williamson C., Moolenaar W.H., Beuers U., Oude Elferink R.P. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010, 139:1008-1018.
228. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., Kliewer S., Willson T.M., Edwards P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277:2908-2915.
229. Yu J., Lo J.L., Huang L., Zhao A., Metzger E., Adams A., Meinke P.T., Wright S.D., Cui J. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J. Biol. Chem. 2002, 277:31441-31447.
230. Claudel T., Sturm E., Kuipers F., Staels B. The farnesoid X receptor: a novel drug target?. Expert Opin. Investig. Drugs 2004, 13:1135-1148.
231. Moschetta A., Bookout A.L., Mangelsdorf D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 2004, 10:1352-1358.
232. Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?. Hepatology 2004, 40:260-263.
233. Gadaleta R.M., van Mil S.W., Oldenburg B., Siersema P.D., Klomp L.W., van Erpecum K.J. Bile acids and their nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal disease. Biochim. Biophys. Acta 2010, 1801:683-692.
234. Beigneux A.P., Moser A.H., Shigenaga J.K., Grunfeld C., Feingold K.R. The acute phase response is associated with retinoid X receptor repression in rodent liver. J. Biol. Chem. 2000, 275:16390-16399.
235. Kim M.S., Shigenaga J., Moser A., Feingold K., Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J. Biol. Chem. 2003, 278:8988-8995.
236. Feingold K.R., Spady D.K., Pollock A.S., Moser A.H., Grunfeld C. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J. Lipid Res. 1996, 37:223-228.
237. Memon R.A., Moser A.H., Shigenaga J.K., Grunfeld C., Feingold K.R. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. Potential role of hepatocyte nuclear factor-1. J. Biol. Chem. 2001, 276:30118-30126.
238. Zhang S., Liu Q., Wang J., Harnish D.C. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem. Biophys. Res. Commun. 2009, 379:476-479.
239. Wang Y.D., Chen W.D., Wang M., Yu D., Forman B.M., Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008, 48:1632-1643.
240. Yang F., Huang X., Yi T., Yen Y., Moore D.D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67:863-867.
241. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., Gonzalez F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
242. Zhang S., Wang J., Liu Q., Harnish D.C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009.
243. Mencarelli A., Renga B., Migliorati M., Cipriani S., Distrutti E., Santucci L., Fiorucci S. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol. 2009, 183:6657-6666.
244. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004, 127:1497-1512.
245. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pruzanski M., Morelli A., Pellicciari R. A FXR-SHP regulatory cascade modulates TIMP-1 and MMPs expression in HSCs and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 2005.
246. Fickert P., Fuchsbichler A., Moustafa T., Wagner M., Zollner G., Halilbasic E., Stoger U., Arrese M., Pizarro M., Solis N., Carrasco G., Caligiuri A., Sombetzki M., Reisinger E., Tsybrovskyy O., Zatloukal K., Denk H., Jaeschke H., Pinzani M., Trauner M. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am. J. Pathol. 2009, 175:2392-2405.
247. Cho J.Y., Matsubara T., Kang D.W., Ahn S.H., Krausz K.W., Idle J.R., Luecke H., Gonzalez F.J. Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. J. Lipid Res. 2010, 51:1063-1074.
248. Marschall H.U., Wagner M., Zollner G., Fickert P., Diczfalusy U., Gumhold J., Silbert D., Fuchsbichler A., Benthin L., Grundstrom R., Gustafsson U., Sahlin S., Einarsson C., Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005, 129:476-485.
249. Huang W., Zhang J., Moore D.D. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J. Clin. Invest. 2004, 113:137-143.
250. Nakamuta M., Enjoji M., Kotoh K., Shimohashi N., Tanabe Y. Long-term fibrate treatment for PBC. J. Gastroenterol. 2005, 40:546-547.
251. Carrella M., Feldman D., Cogoi S., Csillaghy A., Weinhold P.A. Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin-treated rat. Hepatology 1999, 29:1825-1832.
252. Chianale J., Vollrath V., Wielandt A.M., Amigo L., Rigotti A., Nervi F., Gonzalez S., Andrade L., Pizarro M., Accatino L. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem. J. 1996, 314(Pt 3):781-786.
253. Hooiveld G.J., Vos T.A., Scheffer G.L., Van Goor H., Koning H., Bloks V., Loot A.E., Meijer D.K., Jansen P.L., Kuipers F., Muller M. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 1999, 117:678-687.
254. Miranda S., Vollrath V., Wielandt A.M., Loyola G., Bronfman M., Chianale J. Overexpression of mdr2 gene by peroxisome proliferators in the mouse liver. J. Hepatol. 1997, 26:1331-1339.
255. Ghose R., Mulder J., von Furstenberg R.J., Thevananther S., Kuipers F., Karpen S.J. Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. J. Hepatol. 2007, 46:115-123.
256. Pascussi J.M., Busson-Le Coniat M., Maurel P., Vilarem M.J. Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol. Endocrinol. 2003, 17:42-55.
257. Tanaka H., Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 1992, 188:942-948.
258. Miura T., Ouchida R., Yoshikawa N., Okamoto K., Makino Y., Nakamura T., Morimoto C., Makino I., Tanaka H. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J. Biol. Chem. 2001, 276:47371-47378.
259. Weitzel C., Stark D., Kullmann F., Scholmerich J., Holstege A., Falk W. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur. J. Gastroenterol. Hepatol. 2005, 17:169-177.
260. Sola S., Amaral J.D., Castro R.E., Ramalho R.M., Borralho P.M., Kren B.T., Tanaka H., Steer C.J., Rodrigues C.M. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 2005, 42:925-934.
261. Lammert F., Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005, 2:423-433.
262. Wittenburg H., Lammert F. Genetic predisposition to gallbladder stones. Semin. Liver Dis. 2007, 27:109-121.
263. Jacquemin E., De Vree J.M., Cresteil D., Sokal E.M., Sturm E., Dumont M., Scheffer G.L., Paul M., Burdelski M., Bosma P.J., Bernard O., Hadchouel M., Elferink R.P. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001, 120:1448-1458.
264. Rosmorduc O., Hermelin B., Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001, 120:1459-1467.
265. Rosmorduc O., Hermelin B., Boelle P.Y., Parc R., Taboury J., Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003, 125:452-459.
266. van Mil S.W., van der Woerd W.L., van der Brugge G., Sturm E., Jansen P.L., Bull L.N., van den Berg I.E., Berger R., Houwen R.H., Klomp L.W. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004, 127:379-384.
267. Schafmayer C., Tepel J., Franke A., Buch S., Lieb S., Seeger M., Lammert F., Kremer B., Folsch U.R., Fandrich F., Schreiber S., Hampe J. Investigation of the Lith1 candidate genes ABCB11 and LXRA in human gallstone disease. Hepatology 2006, 44:650-657.
268. Wittenburg H., Lyons M.A., Li R., Churchill G.A., Carey M.C., Paigen B. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology 2003, 125:868-881.
269. Goralski K.B., Sinal C.J. Chipping away at gallstones. Nat. Med. 2004, 10:1301-1302.
270. Nilsell K. Bile acid pool size and gallbladder storage capacity in gallstone disease. Scand. J. Gastroenterol. 1990, 25:389-394.
271. Berr F., Pratschke E., Fischer S., Paumgartner G. Disorders of bile acid metabolism in cholesterol gallstone disease. J. Clin. Invest. 1992, 90:859-868.
272. Kern F. Effects of dietary cholesterol on cholesterol and bile acid homeostasis in patients with cholesterol gallstones. J. Clin. Invest. 1994, 93:1186-1194.
273. Moore D.D. Physiology: sister act. Science 2007, 316:1436-1438.
274. Bennion L.J., Grundy S.M. Effects of obesity and caloric intake on biliary lipid metabolism in man. J. Clin. Invest. 1975, 56:996-1011.
275. Diehl A.K. Cholelithiasis and the insulin resistance syndrome. Hepatology 2000, 31:528-530.
276. Nervi F., Miquel J.F., Alvarez M., Ferreccio C., Garcia-Zattera M.J., Gonzalez R., Perez-Ayuso R.M., Rigotti A., Villarroel L. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J. Hepatol. 2006, 45:299-305.
277. Tsai C.J., Leitzmann M.F., Willett W.C., Giovannucci E.L. Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women. Gastroenterology 2005, 129:105-112.
278. Biddinger S.B., Haas J.T., Yu B.B., Bezy O., Jing E., Zhang W., Unterman T.G., Carey M.C., Kahn C.R. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat. Med. 2008, 14:778-782.